GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Cv Therapeutics, Inc. (CVTX) [hlAlert]

Rating:
Buy CVTX
up 120.61 %

Cv Therapeutics, Inc. (CVTX) rated Buy with price target $42 by Cantor Fitzgerald

Posted on: Monday,  Oct 6, 2008  8:25 AM ET by Cantor Fitzgerald

Cantor Fitzgerald rated Buy Cv Therapeutics, Inc. (NASDAQ: CVTX) on 10/06/2008. Previously Cantor Fitzgerald rated Buy Cv Therapeutics, Inc. (NASDAQ: CVTX) on
12/03/2007., when the stock price was $9.07. Since then, Cv Therapeutics, Inc. has gained 120.62% as of 04/17/2009's recent price of $20.01.
If you would have followed the previous Cantor Fitzgerald's recommendation on CVTX, you would have gained 120.61% of your investment in 501 days.

CV Therapeutics is a biopharmaceutical company engaged in the discoveryand development of new small molecule drugs to treat cardiovascular disease, the leading cause of death in the United States. The company has several research and preclinical development programs designed to bring additional drug candidates into human clinical testing. The company is conducting clinical trials for two of our drug candidates, including ranolazine, which is in its second Phase III trial.

Cantor U.S. Equity Research provides timely and insightful opinions on select stocks. We look at key drivers of the stock price, including company and industry fundamentals, capital markets influences and overall economic trends to provide critical and in-depth analysis. Our focus is on small and mid-cap companies in the following sectors: * Marine Transportation * Life Sciences * Clean Technology & Energy Efficiency * Real Estate * Communications Technology * Internet * Enterprise Software
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/6/2008 8:25 AM Buy
None
9.79 42.00
as of 12/24/2008
1 Week   
1 Month up  0.95 %
3 Months up  75.06 %
1 YTD up  117.26 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/3/2007 9:25 AM Buy
None
9.07 40.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy